Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methyltransferase like 14 (METTL14) is a protein encoded by the human METTL14 gene. It functions primarily as a structural component within the N6-methyladenosine (m6A) methyltransferase complex, forming a heterodimer with METTL3. While METTL3 provides catalytic activity for transferring a methyl group from S‑adenosylmethionine to adenosine residues in RNA, METTL14 acts mainly as an RNA-binding scaffold that recognizes substrate RNAs rather than catalyzing reactions itself. The resulting m6A modification regulates various aspects of messenger RNA metabolism including splicing, stability, degradation, and translation efficiency. This process is essential for normal development—such as embryonic stem cell differentiation and neurogenesis—and has been implicated in diseases including several cancers. Aberrant function or expression can contribute to oncogenesis or other pathologies through dysregulation of gene expression at the post-transcriptional level[1][2][5].
Drugs targeting this molecule would likely modulate mRNA methylation by affecting the activity or assembly of the METTL3-METTL14 complex; no approved drugs directly target METTL14 as of now.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methyltransferase like 14 (METTL14).